Nasdaq · CIK 0001554818
AUUD AUDDIA INC.
Insider trading from SEC Form 4. Last filing Jan 2, 2026. Close $1.06 on Oct 9, 2026, +29% from the 52-week low and -93% from the high.
In brief
AUDDIA INC. (AUUD) has 12 SEC Form 4 filings on file from 8 insiders, the latest filed on Jan 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at AUUD. The newest: Jeffrey John Thramann (CEO and Executive Chairman) sold $2,197 of stock on Dec 31, 2025, filed Jan 2, 2026, scored 35 (weak).
1 Form 144 notice of planned sales is on file, the latest filed Dec 29, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AUDDIA INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | Jeffrey John Thramann CEO and Executive Chairman sell | $2,197 2,301 shares | -49% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 29, 2025 | Jeffrey J. Thramann CEO; Director | 2,301 0.07% of outstanding | $2,393 | Dec 29, 2025 | none |
Transactions
Every row filed, 21 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | Jeffrey John Thramann CEO and Executive Chairman | SOpen-market sale Common Stock | -2,301 | $0.96 | $2,197 | 2,356 | Jan 2, 2026 |
| Sep 10, 2025 | Emmanuel de Boucaud director | AGrant or award Options for Common Stock (right to buy)derivative | +21,455 | $0.00 | $0 | 21,455 | Sep 12, 2025 |
| Sep 10, 2025 | John Edward Mahoney Chief Financial Officer | AGrant or award Options for Common Stock (right to buy)derivative | +8,317 | $0.00 | $0 | 8,317 | Sep 12, 2025 |
| Sep 10, 2025 | Nicholas Balletta director | AGrant or award Options for Common Stock (right to buy)derivative | +21,455 | $0.00 | $0 | 21,455 | Sep 12, 2025 |
| Sep 10, 2025 | Jeffrey John Thramann Executive Chairman and CEO | AGrant or award Options for Common Stock (right to buy)derivative | +23,783 | $0.00 | $0 | 23,783 | Sep 12, 2025 |
| Sep 10, 2025 | Joshua Adam Sroge director | AGrant or award Options for Common Stock (right to buy)derivative | +21,455 | $0.00 | $0 | 21,455 | Sep 12, 2025 |
| Feb 16, 2025 | Jeffrey John Thramann Executive Chairman | MOption exercise Common Stock | +2,000 | - | - | 79,836 | Feb 19, 2025 |
| Feb 16, 2025 | Stephen Deitsch director | MOption exercise Common Stock | +915 | - | - | 3,111 | Feb 19, 2025 |
| Feb 16, 2025 | Timothy J. Hanlon director | MOption exercise Common Stock | +915 | - | - | 3,111 | Feb 19, 2025 |
| Feb 16, 2025 | Thomas Carl Birch director | MOption exercise Common Stock | +915 | - | - | 3,111 | Feb 19, 2025 |
| Feb 16, 2025 | Timothy J. Hanlon director | FTax withholding Common Stock | -275 | $0.51 | $140 | 2,836 | Feb 19, 2025 |
| Feb 16, 2025 | Stephen Deitsch director | FTax withholding Common Stock | -275 | $0.51 | $140 | 2,836 | Feb 19, 2025 |
| Feb 16, 2025 | Thomas Carl Birch director | FTax withholding Common Stock | -275 | $0.51 | $140 | 2,836 | Feb 19, 2025 |
| Feb 16, 2025 | Jeffrey John Thramann Executive Chairman | FTax withholding Common Stock | -690 | $0.51 | $352 | 79,146 | Feb 19, 2025 |
| Feb 16, 2025 | Timothy J. Hanlon director | MOption exercise Restricted Stock Unitsderivative | -915 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 16, 2025 | Thomas Carl Birch director | MOption exercise Restricted Stock Unitsderivative | -915 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 16, 2025 | Jeffrey John Thramann Executive Chairman | MOption exercise Restricted Stock Unitsderivative | -2,000 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 16, 2025 | Stephen Deitsch director | MOption exercise Restricted Stock Unitsderivative | -915 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Dec 31, 2024 | Jeffrey John Thramann Executive Chairman | AGrant or award Options for Common Stock (right to buy)derivative | +500,000 | $0.00 | $0 | 500,000 | Jan 3, 2025 |
| Dec 12, 2023 | John Edward Mahoney Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Dec 13, 2023 |
| Dec 12, 2023 | John Edward Mahoney Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +192,500 | $0.00 | $0 | 467,500 | Dec 13, 2023 |
Insiders
Everyone who has filed a Form 4 here.
- Nicholas Ballettadirector
- Thomas Carl Birchdirector
- Stephen Deitschdirector
- Timothy J. Hanlondirector
- John Edward MahoneyChief Financial Officer
- Joshua Adam Srogedirector
- Jeffrey John ThramannCEO and Executive Chairman
- Emmanuel de Boucauddirector
Questions about AUUD
Answered from the filings on this page, as of the latest one.
Are insiders buying AUUD?
No. In the last 90 days no insider at AUDDIA INC. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade AUUD on the open market?
Jeffrey John Thramann (CEO and Executive Chairman) sold $2,197 of AUUD on Dec 31, 2025 and filed the Form 4 on Jan 2, 2026. InsiderTell scored 35 (weak).
How many insiders file Form 4 at AUDDIA INC.?
8 people have filed a Form 4 at AUDDIA INC., among them Nicholas Balletta (director), Thomas Carl Birch (director), Stephen Deitsch (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.